Oculis (NASDAQ:OCS) Shares Gap Up – Still a Buy?

Oculis Holding AG (NASDAQ:OCS) gapped up before the market opened on Thursday . The stock had previously closed at $16.50, but opened at $16.98. Oculis shares last traded at $16.98, with a volume of 700 shares traded.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Oculis in a report on Monday, November 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Oculis currently has a consensus rating of “Buy” and a consensus target price of $29.20.

Oculis Price Performance

The business’s 50-day simple moving average is $15.72 and its 200 day simple moving average is $13.18. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $692.15 million, a P/E ratio of -8.85 and a beta of -0.34.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.